EUPRAXIA PHARMACEUTICALS INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
The yearly report of certain Canadian companies, filed under a joint US and Canadian system. It is the main yearly account these companies give US investors, largely as filed in Canada.
FY2024 · Filed Mar 20, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.3 · Summary of Quarterly Results
Summary of Quarterly Results
The information in the tables below has been derived from the Company’s audited consolidated financial statements. Effective December 31, 2023, the Company transitioned to U.S. GAAP and changed its reporting currency to USD from CDN. As such, all prior amounts originally reported in CDN are now reported in USD. The change in reporting currency was made to enhance comparability of the Company’s results with other publicly traded companies in the life sciences industry. The Canadian dollar continues to be the functional currency of the Company. In addition, all quarters have been retrospectively restated for the adoption of U.S. GAAP effective December 31, 2023.
The Company’s quarterly operating results have varied substantially in the past and may vary substantially in the future. Accordingly, the information below is not necessarily indicative of results for any future quarter.
| Dec 31,2024 | Sep 30,2024 | Jun 30,2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30,2023 (Restated) | Jun 30, 2023 (Restated) | Mar 31,2023 (Restated) | |
|---|---|---|---|---|---|---|---|---|
| $ | $ | $ | $ | $ | $ | $ | $ | |
| Total Revenue | - | - | - | - | - | - | - | - |
| Total net loss | (7,532,342) | (5,991,320) | (6,063,894) | (6,156,933) | (10,607,396) | (4,896,082) | (9,506,442) | (3,956,088) |
| Loss per share, basic and diluted (Owners of the Company) | (0.21) | (0.17) | (0.17) | (0.21) | (0.38) | (0.18) | (0.43) | (0.18) |
The Company has incurred net losses in each of its preceding eight quarters as a result of continued activities associated with the Phase 2 clinical trial for EP-104IAR and the Phase 1b/2a clinical trial of EP-104GI. This trend is expected to continue into the future as we make further investments in our EP-104 programs. Research and development expenses are expected to remain high as we undertake clinical trials and incur significant costs for CROs and consultants, and further investment in additional drug candidates in support of broader pipeline development. General and administrative expenses are likely to remain high in the future as a result of ongoing costs associated with public company compliance.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.